Post-hoc Analysis of Outcome of Intravenous Thrombolysis in Infarcts of Infratentorial Localization in the WAKE-UP Trial

Introduction: In WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke), patients with an acute stroke of unknown onset time were randomized to treatment with intravenous alteplase or placebo, guided by MRI. Methods: In this exploratory post-hoc secondary analysis we compared clinical and imaging data, as well as treatment effects and safety of intravenous thrombolysis between patients with infra- vs. supratentorial stroke. Results: Forty-eight out of 503 randomized patients (9.5%) presented with a stroke involving the cerebellum or brainstem. Patients with infratentorial stroke were younger compared to patients with supratentorial stroke (mean age 60 vs. 66 years), more frequently male (85 vs. 62%), and less severely affected (median NIHSS 4.5 vs. 6.0). There was no heterogeneity for treatment effect between supratentorial (OR 1.67 95% CI 1.11–2.51) and infratentorial (OR 1.31 95% CI 0.41–4.22) sub-groups (test for interaction p = 0.70). In patients with infratentorial stroke, favorable outcome [a score of 0–1 on the modified Rankin scale (mRS) at 90 days] was observed in 12/22 patients (54.5%) in the alteplase group and in 13/25 patients (52.0%) in the placebo group (p = 0.59). The primary safety endpoint (death or mRS 4–6 at day 90) occurred in three patients of the alteplase group (13.6%) and three patients in the placebo group (12.0%); p = 0.74. Discussion: WAKE-UP was underpowered for demonstrating treatment effect in subgroup analyses however, based on our current results, there is no evidence to recommend withholding MRI-guided thrombolysis in patients with unknown onset stroke of infratentorial localization.

[1]  C. Anderson,et al.  NIHSS cut point for predicting outcome in supra- vs infratentorial acute ischemic stroke , 2018, Neurology.

[2]  C. Gerloff,et al.  MRI‐Guided Thrombolysis for Stroke with Unknown Time of Onset , 2018, The New England journal of medicine.

[3]  P. Kaňovský,et al.  Predictors for Intracranial Hemorrhage Following Intravenous Thrombolysis in Posterior Circulation Stroke , 2018, Translational Stroke Research.

[4]  M. Chen,et al.  NubuckLight Sarto Smooth Smooth Richland Franco Bone Black Nubuck Satin Satin 3 xgZx7qY4 --wildwoodmotorsports.com , 2017 .

[5]  P. Kaňovský,et al.  Posterior vs. Anterior Circulation Infarction: Demography, Outcomes, and Frequency of Hemorrhage after Thrombolysis , 2015, International journal of stroke : official journal of the International Stroke Society.

[6]  J. Fiebach,et al.  Difficulty of MRI Based Identification of Lesion Age by Acute Infra-Tentorial Ischemic Stroke , 2014, PloS one.

[7]  Ivana Galinovic,et al.  DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study , 2011, The Lancet Neurology.

[8]  S. Engelter,et al.  Outcomes of Intravenous Thrombolysis in Posterior Versus Anterior Circulation Stroke , 2011, Stroke.

[9]  K. Kimura,et al.  FLAIR can estimate the onset time in acute ischemic stroke patients , 2010, Journal of the Neurological Sciences.

[10]  S. Warach,et al.  Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study , 2009, The Lancet Neurology.

[11]  George Howard,et al.  Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes , 2008, The Lancet Neurology.

[12]  H. Moriwaki,et al.  Baseline NIH Stroke Scale Score predicting outcome in anterior and posterior circulation strokes , 2008, Neurology.

[13]  Werner Hacke,et al.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.

[14]  P. Trouillas,et al.  Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. , 2006, Stroke.

[15]  Erich Bluhmki,et al.  Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II) , 2001, Stroke.

[16]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[17]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[18]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .